troglitazone has been researched along with Kidney Failure in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Kidney Failure: A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ogawa, M | 1 |
| Hirawa, N | 1 |
| Tsuchida, T | 1 |
| Eguchi, N | 1 |
| Kawabata, Y | 1 |
| Numabe, A | 1 |
| Negoro, H | 1 |
| Hakamada-Taguchi, R | 1 |
| Seiki, K | 1 |
| Umemura, S | 1 |
| Urade, Y | 1 |
| Uehara, Y | 1 |
1 other study available for troglitazone and Kidney Failure
| Article | Year |
|---|---|
Urinary excretions of lipocalin-type prostaglandin D2 synthase predict the development of proteinuria and renal injury in OLETF rats.
Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Hypoglycemic Agents; Immunoenz | 2006 |